Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system
Open Access
- 1 November 1999
- journal article
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 68 (5) , 1756-1760
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Treatment of Human Breast Cancer in a Brain Metastatic Model by G207, a Replication-Competent Multimutated Herpes Simplex Virus 1Human Gene Therapy, 1998
- Adenovirus-Mediated Herpes Simplex Virus Thymidine Kinase/Ganciclovir Gene Therapy in Patients with Localized Malignancy: Results of a Phase I Clinical Trial in Malignant MesotheliomaHuman Gene Therapy, 1998
- Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukinsGene Therapy, 1998
- Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expressionGene Therapy, 1997
- Safety of Intrapleurally Administered Recombinant Adenovirus Carrying Herpes Simplex Thymidine Kinase DNA Followed by Ganciclovir Therapy in Nonhuman PrimatesHuman Gene Therapy, 1996
- The Role of Immunosuppression in the Efficacy of Cancer Gene Therapy Using Adenovirus Transfer of the Herpes Simplex Thymidine Kinase GeneAnnals of Surgery, 1995
- ICP34.5 influences herpes simplex virus type 1 maturation and egress from infected cells in vitroJournal of General Virology, 1994
- The herpes simplex virus type 1 strain 17+ 34.5 deletion mutant 1716 is avirulent in SCID miceJournal of General Virology, 1994
- Replicating vectors for gene therapy of cancer: risks, limitations and prospectsEuropean Journal of Cancer, 1994
- Combination effect of vaccination with IL2 and IL4 cdna transfected cells on the induction of a therapeutic immune response against lewis lung carcinoma cellsInternational Journal of Cancer, 1993